BMO Capital Markets Lowers Penumbra (PEN) to Market Perform

Penumbra (NYSE:PEN) was downgraded by research analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday. They currently have a $110.00 price objective on the stock, down from their prior price objective of $117.00. BMO Capital Markets’ price target indicates a potential upside of 11.45% from the stock’s previous close. The analysts noted that the move was a valuation call.

Several other equities analysts have also recently weighed in on PEN. BidaskClub cut Penumbra from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Zacks Investment Research upgraded Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, August 30th. Finally, Canaccord Genuity lifted their target price on Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th.

Penumbra (PEN) traded up $2.95 during midday trading on Tuesday, reaching $98.70. The company’s stock had a trading volume of 257,130 shares, compared to its average volume of 155,495. Penumbra has a fifty-two week low of $62.42 and a fifty-two week high of $116.35.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.07. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $79.17 million. Penumbra had a negative return on equity of 1.95% and a negative net margin of 2.19%. The firm’s revenue for the quarter was up 24.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.04) EPS. equities research analysts expect that Penumbra will post -0.15 earnings per share for the current fiscal year.

In other news, EVP Robert D. Evans sold 2,859 shares of Penumbra stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $90.00, for a total value of $257,310.00. Following the completion of the transaction, the executive vice president now owns 11,704 shares in the company, valued at approximately $1,053,360. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Sridhar Kosaraju sold 6,026 shares of Penumbra stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $103.83, for a total value of $625,679.58. The disclosure for this sale can be found here. In the last quarter, insiders sold 301,079 shares of company stock valued at $31,150,834. Company insiders own 13.50% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Penumbra by 10.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock worth $102,000 after purchasing an additional 114 shares during the period. Teacher Retirement System of Texas bought a new stake in shares of Penumbra during the 3rd quarter worth approximately $214,000. Verition Fund Management LLC bought a new stake in shares of Penumbra during the 2nd quarter worth approximately $213,000. Ameritas Investment Partners Inc. lifted its stake in shares of Penumbra by 10.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock worth $226,000 after acquiring an additional 250 shares during the last quarter. Finally, Prudential Financial Inc. bought a new stake in shares of Penumbra during the 2nd quarter worth approximately $252,000. Hedge funds and other institutional investors own 71.71% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Market News and is the property of of American Market News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/17/bmo-capital-markets-lowers-penumbra-pen-to-market-perform.html.

About Penumbra

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.